Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3451838 in Healthy Subjects
NCT03692949Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3451838 in migraine and Cluster Headache (CH) (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With Any Treatment Emergent Adverse Event at 20 weeks and Number of Participants With One or More Serious Adverse Events at 20 weeks. Started Dec 2018; status: completed.
02
Drugs
LY3451838
03
Conditions
migraineCluster Headache (CH)
Beyond the preview
Go deeper on NCT03692949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692949.